0000899243-21-016315.txt : 20210419 0000899243-21-016315.hdr.sgml : 20210419 20210419213240 ACCESSION NUMBER: 0000899243-21-016315 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210415 FILED AS OF DATE: 20210419 DATE AS OF CHANGE: 20210419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: dEsparbes Eric CENTRAL INDEX KEY: 0001622268 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 21836095 MAIL ADDRESS: STREET 1: THERAVANCE, INC. STREET 2: 951 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENITY, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-15 0 0001580063 PROGENITY, INC. PROG 0001622268 dEsparbes Eric C/O PROGENITY, INC. 4330 LA JOLLA VILLAGE DRIVE, SUITE 200 SAN DIEGO CA 92122 0 1 0 0 Chief Financial Officer Common Stock 2021-04-15 4 A 0 123382 0.00 A 215805 D Common Stock 2021-04-15 4 F 0 13690 3.41 D 202115 D Stock Option (Right to Buy) 3.41 2021-04-15 4 A 0 175790 0.00 A 2031-04-15 Common Stock 175790 175790 D Consists of 123,382 restricted stock units, 39,589 of which vested on the grant date and 20,948 of which will vest on May 15, 2022, with the remaining shares vesting in equal semi-annual installments through May 15, 2025, subject to the Reporting Person's continued service to the Issuer. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 39,589 vested restricted stock units on April 15, 2021. This option represents the right to purchase 175,790 shares of the Issuer's common stock, 3,661 of which vested upon grant, with the remaining shares vesting in equal monthly installments through March 15, 2025, subject to the Reporting Person's continued service to the Issuer. /s/ Will Pridgen, Attorney-in-Fact for Eric d'Esparbes 2021-04-19